JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, J.
Right arrow Articles by Herron, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, J.
Right arrow Articles by Herron, G. S.

J Biol Chem, Vol. 274, Issue 37, 26141-26148, September 10, 1999


Human Endothelial Cell Life Extension by Telomerase Expression*

Jiwei YangDagger §, Edwin Chang§parallel , Athena M. Cherry, Charles D. Bangs, Yoko Oeiparallel , Andrea Bodnarparallel , Adrienne Bronsteinparallel , Choy-Pik Chiuparallel , and G. Scott HerronDagger **

From the Departments of Dagger  Dermatology and  Cytogenetics, Stanford University School of Medicine, Stanford, California 94305-5486 and parallel  Geron Corp., Menlo Park, California 94025-1130

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Normal human endothelial cells, like other somatic cells in culture, divide a limited number of times before entering a nondividing state called replicative senescence. Expression of the catalytic component of human telomerase, human telomerase reverse transcriptase (hTERT), extends the life span of human fibroblasts and retinal pigment epithelial cells beyond senescence without causing neoplastic transformation (Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., and Wright, W. E. (1998) Science 279, 349-352; Jiang, X., Jimenez, G., Chang, E., Frolkis, M., Kusler, B., Sage, M., Beeche, M., Bodnar, A., Wahl, G., Tlsty, T., and Chiu, C.-P. (1999) Nat. Genet. 21, 111-114). Here, we show that both human large vessel and microvascular endothelial cells also bypass replicative senescence after introduction of hTERT. For the first time, we report that hTERT expression in these life-extended vascular cells does not affect their differentiated and functional phenotype and that these cells maintain their angiogenic potential in vitro. Furthermore, hTERT(+) microvascular endothelial cells have normal karyotype, and hTERT(+) endothelial cell strains do not exhibit a transformed phenotype. Relative to parental cells at senescence, hTERT-expressing endothelial cells exhibit resistance to induction of apoptosis by a variety of different conditions. Such characteristics are highly desirable for designing vascular transplantation and gene therapy delivery systems in vivo.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The integrity of endothelial cell (EC)1 function is compromised with advancing age and directly contributes to age-dependent impairment of angiogenesis and development of vascular diseases (1, 2). Aging of the vasculature is also associated with a number of phenotypic and hemodynamic changes commonly observed in cardiovascular disease states (3, 4). Some of these phenotypic alterations have been found to occur in ECs undergoing senescence in vitro and include increased expression of proteolytic activity (5, 6), inflammatory markers (7-9), and vasoconstrictors and reduced expression of vasodilators and vasoprotective factors (3, 10-12).

The adult endothelium in vivo is remarkably quiescent (13, 14), but ECs can be activated to proliferate, e.g. following traumatic injury, inflammation, and tumor formation or in response to physiologic cues during hair growth and ovarian cycling (15, 16). This property has allowed the in vitro cultivation and expansion of ECs from many different tissues. Like most human somatic cells, however, ECs undergo replicative senescence in vitro after a finite number of divisions, which can vary between 20 and 60 population doublings (PDLs) depending on the tissue of origin and culture conditions (17).

Efforts to extend the life of ECs have focused on ectopic expression of viral oncogenes (18-21), spontaneous transformation (22), addition of exogenous growth factors, and provision of supportive matrix components (17). One EC-specific growth factor, vascular endothelial cell growth factor has been shown to both delay the onset of human dermal microvascular EC (HDMEC) senescence (23) and block anoikis (anchorage disruption-induced apoptosis) by producing a permissive matrix that supports EC adhesion and proliferation (24). ECs will eventually undergo replicative senescence regardless of exogenous growth factors and matrix components unless they are transformed. Immortal EC lines generated by viral or spontaneous transformation, however, invariably fail to exhibit physiologic distal proliferative signaling pathways and eventually lose important differentiated EC functions.

Another way to bypass senescence has recently been achieved by ectopic expression of the human telomerase reverse transcriptase (hTERT) gene, which imparts replicative immortality to fibroblasts and retinal pigment epithelial (RPE) cells (25) without converting to a neoplastic transformed phenotype (26, 27). A recent finding that both hTERT expression and inactivation of pRb or p16 is required to immortalize primary human keratinocytes and mammary epithelial cells raises the issue of cell type specificity in hTERT-mediated immortalization (28). In this report, we show that both large and small vessel-derived ECs, like dermal fibroblasts, can be effectively immortalized by hTERT alone in the absence of malignant transformation. In addition, we show for the first time that hTERT-immortalized ECs exhibit functional and morphogenetic characteristics of parental cells. These hTERT-EC lines may also display a survival advantage beyond the hurdling of replicative senescence, as they appear to be more resistant to programmed cell death. Such characteristics may be useful in the design of vascular model systems and therapeutic stratagies for treating age-related diseases of the vasculature.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Establishment of Endothelial Cell Cultures-- Human umbilical vein endothelial cells (HUVECs) were given as a gift from Drs. Thomas Maciag (Maine Medical Center) and Susan Garfinkel (American Red Cross). Human saphenous vein endothelial cells (HSVECs) came from Vascular Endothelial Cell (VEC) Laboratories. Human aortic endothelial cells (HAECs), human coronary arterial endothelial cells (HCAECs), and part of HDMECs for making hTERT1 were purchased from Clonetics. hTERT3 was established in our laboratory by preparation of primary HDMECs from neonatal foreskin as described previously (29, 30). Growth media were from EBM-2 (or EBM) MV BulletKit (Clonetics). Our primary parental HDMECs for hTERT3 was purified with PECAM-coated beads (Sigma) and recovered with a magnetic particle concentrator (Promega). A spontaneously transformed HUVEC line, ECV304, was obtained from ATCC.

Gene Transduction-- Gene transfer was achieved by either electroporation-based transfection or retrovirus-mediated gene transfer. For electroporation, pZeoSV-hTERT, a derivative of pZeoSV (Invitrogen) was used to transfect HUVECs (25). Two different versions of retroviruses were used to transduce hTERT genes to the ECs. pBabe-hTERT (a generous gift from Dr. Woody Wright, University of Texas Southwestern Medical Center, Dallas, TX) was used for HAECs, HCAECs, and HSVECs (31) and LZRS-hTERT was used for HDMECs (32). The expression of hTERT for both retroviral vectors was driven by Mololey murine leukemia virus 5'-long terminal repeat promoter. Viral titers determined by the infection of NIH-3T3 cells with pBabe-hTERT or LZRS vector containing enhanced green fluorescent protein reporter gene were estimated at approximately 5 × 106/ml.

Telomeric Repeat Amplification Protocol (TRAP) Assay-- Either a non-amplified conventional standard (33) or a PCR-ELISA-based assay (Roche Molecular Biochemicals) was used to measure the telomerase activity from the hTERT transgene or endogenous telomerase. The standard protocol was used for HUVECs, HAECs, HCAECs and HSVECs, whereas PCR-ELISA was used for HDMECs. For visualizing the DNA ladder with the standard protocol, 1000 or 5000 cell equivalents were analyzed. For PCR-ELISA, 2000 cell equivalents were used. The PCR-ELISA protocol was provided by the assay kit manufacturer (Roche Molecular Biochemicals).

Telomere Length Assay-- Isolation of genomic DNA and Southern blot determination of mean terminal restriction fragment (TRF) were performed according to published procedures (34-36). Briefly, genomic DNA (3 µg) was digested with HinfI/RsaI and run on 0.6% agarose gel. The gel was transferred onto a positively charged nylon membrane, which was hybridized at 65 °C overnight. Hybridization signals were detected by chemiluminescence or radioactivity. Calculation of mean TRF length was done as described previously (37)

RT-PCR for Telomerase Transcripts-- The primers for RT-PCR were as follows: 1) in the hTERT gene, sense, CACCTCACCCACGCGAAAA; antisense, CCAAAGAGTTTGCGACGCATGTT; and 2) at the border of hTERT and retroviral LZRS sequence, sense, TCCTGAAAGCCAAGAACGCA; antisense, GACCAACTGGTAATGGTAGCGA. Total RNA was isolated with TRIZOL (Life Technologies, Inc.). The RT-PCR was performed by a one-step RT-PCR system according to the manufacturer (Life Technologies, Inc.).

Flow Cytometry-- The antibodies used for flow cytometry were anti-PECAM-1 (Becton Dickinson), ICAM-1 (Pharmingen), and Apo2.7 (Immunotech). For stimulated expression studies (e.g. ICAM-1, VCAM-1, and E-selectin) cells were stimulated with TNF-alpha (20 ng/ml) for 15 h before the assay. For detection of the early apoptotic mitochondrial protein 7A6, monoclonal antibody Apo2.7 (38) reactivity was measured after the cells were treated with TNF-alpha (50 ng/ml) + actinomycin D (1 µg/ml), lipopolysaccharide (100 ng/ml) + cycloheximide (50 µg/ml), or UVC light (255 nm for 0.3 min) 16 h prior to the experiments. Another group of cells were serum-starved for 40 h. The cells were incubated with either phosphatidylethanolamine-conjugated primary antibody or unconjugated primary antibody + phosphatidylethanolamine-conjugated secondary antibody at 37 °C. For the annexin V assay, we used all reagents and protocols according to the manufacturer (Roche Molecular Biochemicals). The data were collected and analyzed with CellQuest (Becton Dickinson) or Coulter EPICS Elite ESP system.

Matrigel and 3D Collagen Overlay Assays-- The procedure was as follows. 1) Matrigel (Collaborative Biomedical Products) was placed on ice and allowed to thaw overnight at 4 °C. 350 µl of Matrigel was layered onto a prechilled well of a six-well plate and then placed in an incubator at 37 °C for 30 min until solidified. Parental HUVECs, transformed ECV304 cells, or hTERT-HUVECs (3.5 × 105 cells) in M199, 15% fetal bovine serum, 10 units/ml heparin, 16 µg/ml endothelial cell growth factor (ECGF) (Roche Biomolecules) were seeded onto the matrix and allowed to incubate at 37 °C in a 5% CO2 environment. 2) Primary or hTERT-transduced HDMECs were overlaid with a 1:1 mixture of Vitrogen 100 (Collagen Biomaterials) and 2× Iscove's medium (Life Technologies, Inc.). Solidification of the collagen gel occurred 30 min after neutralization with NaOH, followed by incubation at 37 °C. Plates were photographed at 8 and 24 h using a Zeiss inverted microscope.

Cell Death ELISA-- Cells were cultured in 48-well plates and maintained at confluence for 2 days before the assay. The reagents and protocols were from Roche Molecular Biochemicals. Briefly, plates were centrifuged for 10 min at 200 × g, and supernatants were removed. Cells were then lysed for 30 min at room temperature, and plates were recentrifuged. 10% (v/v) of the supernatant was used for incubation with anti-histone-biotin and anti-DNA-peroxidase. After 2 h of incubation, plates were washed three times and incubated with substrate solution. The absorbance was measured at 405 nm with a microplate reader (Bio-Rad).

Karyotype Analysis-- Following mitotic arrest with Colcemid®, monolayer cell cultures in log-phase growth were harvested by standard cytogenetic methods of trypsin dispersal, hypotonic shock with 0.075 M KCl, and fixation with 3:1 methanol/acetic acid fixative (39). Mitotic cells slide preparations were analyzed by the GTW banding method (40).

Senescence-associated (SA) beta -Galactosidase Staining-- SA beta -galactosidase staining was performed as previously published (41). Briefly, primary early passage or senescent and hTERT(+) ECs were washed in phosphate-buffered saline and then fixed in 0.5% glutaraldehyde for 10 min. The cells were washed in phosphate-buffered saline twice and incubated in SA beta -galactosidase stain solution overnight. Color pictures were taken with Zeiss inverted microscope.

Uptake of DiI-acetylated LDL-- Primary and hTERT-infected ECs were incubated in growth medium containing 10 µg/ml of DiI-labeled acetylated LDL (Molecular Probes) for 4 h at 37 °C. The culture plates were then observed under an inverted Zeiss microscopy equipped with a rhodamine filter.

Western Blot Analysis for Retinoblastoma Protein (pRb)-- Western analysis for pRb was performed as we previously described (26). The antibody to pRb (PharMingen) recognizes both hyper- and hypophosphorylated forms of the proteins.

Clonogenic Soft Agar Assay-- Cells were resuspended at 1 × 104 cells/ml in growth medium containing 0.36% agar (Difco). Cell suspension (5 ml) was added to 60-mm plates (Costar) precoated with 0.9% solid agar (5 ml). We counted colonies composed of 40 or more cells after 2-6 weeks.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

hTERT Expression Extends EC Life Span-- Our previous studies showed that ectopic expression of recombinant hTERT reconstituted telomerase efficiently in both dermal fibroblasts and RPE (25). In the present study, we have expressed hTERT in HUVECs by stable transfection and in HAECs, HCAECs, HSVECs, and HDMECs by retroviral transduction. The characteristic DNA ladder of the TRAP assay indicates specific telomerase activity in a representative HUVEC-hTERT clone and transduced HAEC-hTERT and HDMEC-hTERT mass cell cultures (Fig. 1A). A quantitative PCR-ELISA-TRAP shows that telomerase activity of hTERT(+) HDMECs is maintained for over 100 PDLs, and the level of telomerase activity achieved in HDMECs is comparable to that expressed by the 293 human embryonic kidney tumor cell line (Fig. 1B). By contrast, parental HDMECs expressed a low level of endogenous telomerase transiently at early PDLs, consistent with previous reports (42). Using RT-PCR, we have also confirmed the presence of hTERT RNA transcribed from the transduced retroviral vector at PDL 60 in HDMECs (data not shown).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   Telomerase activity and telomere length in human endothelial cells after hTERT expression. A, telomerase activity measured by the TRAP assay (see under "Materials and Methods") was detected in both early (PDL 5) parental HDMECs PD5 and all hTERT-ECs from as little as 1000 cell equivalents, but was not detected in middle or late passage parental, sham-infected (LacZ) or heat-treated (HT) hTERT-HUVECs, hTERT-HAECs, and hTERTHDMECs. B, hTERT-HDMEC telomerase activity was quantified using PCR-ELISA and showed persistent activity up to PDL 100, at levels ranging between 80 and 120% of that of the embryonic kidney tumor cell line, 293. Similar results were obtained from two other human cell strains, hTERT-HCAECs and hTERT-HSVECs. C, TRF length of DNA from hTERT-HDMECs at different PDLs showing loss of telomeric DNA from approximately 9 to 4 kbp spanning PDL 100. D, mean TRF length at the indicated PDLs for four representative hTERT-HUVEC clones showing stabilization of telomere length at approximately 2.5 kbp.

Table I summarizes the maximal PDL number attained for each of the five hTERT(+) EC lines. Different parental EC strains senesced at different PDLs, exhibiting typical flattened cell morphology and unresponsiveness to growth factors (Fig. 2) and showed marked SA beta -galactosidase staining (Table II). By contrast, all hTERT-EC lines resembled young primary ECs in their morphology and growth response, with little or no staining with SA beta -galactosidase activity. Thus, ectopic expression of hTERT in ECs extended the replicative life span of all EC strains examined to over twice that of primary ECs, technically defining these hTERT-EC lines as immortalized (43).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Maximal replication life span of endothelial cells


View larger version (92K):
[in this window]
[in a new window]
 
Fig. 2.   Cell morphology of continuously passaged parental and hTERT-HDMECs as a function of PDL. A early passage, primary parental HDMECs at PDL 6; B, senescent parental HDMEC at PDL 30. C and D, sham-transduced (LacZ) parental HDMECs at PDL 6 (C) and at PDL 30 (D). E and F, hTERT-HDMECs at PDL 6 (E) and at PDL 30 (F). Bar, 10 µm.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Phenotype, function, and karyotype of hTERT(+)-EC cultures
Symbols used in this table are as follows: +, positive from the assay; -, negative from the assay; ND, not determined; N, normal; AB, abnormal; down-arrow , decrease.

To examine the effects of hTERT expression on EC telomeres, we assessed telomere lengths by TRF Southern analysis (see under "Materials and Methods"). Fig. 1C shows the change in telomere length of hTERT(+) HDMEC mass cell cultures as a function of PDL. Telomere shortening was observed up to PDL 100-120 followed by consistent stabilization at approximately 3-4 kbp. Analysis in four different hTERT-HUVEC clones showed similar results, with TRF stabilization at approximately 2.5 kbp by PDL 100-140 (Fig. 1D).

hTERT(+) EC Lines Retain EC Characteristics-- Baseline expression of von Willebrand factor and CD31(PECAM-1) and cytokine-stimulated cell surface expression of inflammatory adhesion molecules, ICAM, VCAM, and E-selectin are regarded as key markers distinguishing ECs from other cell types both in vivo and in vitro (14, 44). Similarly, binding and uptake of acetylated LDL and formation of tubule-like structures in response to matricellular signals also define important EC functions maintained in vitro by primary ECs that have not lost their differentiated phenotype (17). Therefore we have assessed the hTERT-EC lines for EC marker expression and responses to cytokines and matricellular proteins (Figs. 3 and 4 and Table II).


View larger version (92K):
[in this window]
[in a new window]
 
Fig. 3.   Morphogenetic responses of different EC types exposed to Matrigel and 3D collagen. A, early passage primary HUVECs (PDL 27) grown on Matigel formed angiogenic webs as efficiently as hTERT-HUVECs at PDL 127 (B). Similarly, early passage (PDL 5) primary HDMECs formed tubule-like structures after 3D collagen exposure (C), as did hTERT-HDMECs at PDL 50 (D). However, both senescent HUVECs (PDL 50) (E) and the transformed HUVEC line ECV304 (F) failed to respond to Matrigel. Bar, 10 µm.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 4.   Flow cytometric analysis of primary ECs and hTERT-ECs for constitutive PECAM-1 and TNF-alpha -inducible ICAM-1 cell surface expression. A and B, both parental and hTERT-HUVECs and hTERT-HDMECs expressed >90% PECAM (open areas, normal IgG; shaded areas, anti-PECAM IgG). HUVECs (parental and hTERT) (A) and ECV304 (C) expressed little or no basal ICAM (open areas), whereas HDMECs (parental and hTERT) (B) and senescent HUVECs (PDL 50) (C) had higher basal ICAM levels (5-15%). Irrespective of basal levels, ICAM expression was strongly induced in both parental and hTERT-HUVECs and-HDMECs (A and B) by 20 ng/ml of TNF-alpha (shaded area), whereas ICAM expression in senescent HUVECs and ECV304 (C) was not induced by TNF-alpha .

Morphogenetic responses were evaluated by exposing HUVEC parental mass cell cultures at PDL 27 (Fig. 3A) and a representative hTERT(+) HUVEC clone at PDL 127 (Fig. 3B) to Matrigel. Both cell populations responded similarly by efficiently forming "angiogenic webs," whereas late passage, senescent PDL 50 HUVECs (Fig. 3E) and a spontaneously transformed HUVEC line, ECV304 (Fig. 3F), did not. Similar results were obtained for both parental HDMECs and hTERT(+) HDMECs exposed to 3D type I collagen (Fig. 3, C and D), and we found that these cells also form tubule-like structures in response to Matrigel. Senescent HDMECs did not form tubules in 3D collagen. As in parental cell lines, some variability in tubule pattern formation was apparent among different hTERT-EC strains (see Table II).

Cell surface expression of PECAM-1 by unstimulated parental HUVECs and an hTERT(+) HUVEC clone at PDL 120 (Fig. 4A) showed similar 90-95% immunoreactivity. Likewise, parental HDMEC and hTERT(+) HDMEC lines showed high PECAM-1 reactivity (Fig. 4B). Expression of Von Willebrand factor and LDL uptake also showed no differences between parental and hTERT-EC lines (Table II). Basal and TNF-alpha -stimulated cell surface expression of ICAM-1, VCAM-1, and E-selectin were similar in both parental and hTERT-EC lines (Fig. 4, A and B, Table II). By contrast, senescent HUVECs expressed high level of ICAM-1, which was not stimulated by TNF-alpha , and ECV304 showed both low baseline and stimulated ICAM expression. Taken together, the data show that hTERT(+) EC lines continuously passaged in vitro for 3-5 times the normal replicative life span of primary ECs exhibit both the functional and differentiated phenotype of early passage, primary ECs.

hTERT-ECs Maintain Growth and Cell Cycle Control Patterns Similar to Parental ECs-- We investigated the growth of hTERT(+) EC lines and found no significant differences in their growth rates compared with parental ECs prior to senescence. The growth curves shown in Fig. 5A are representative of all large vessel hTERT-EC lines and indicate no alteration in growth rates with continuous passage in vitro. Although mitotic rates were not analyzed in detail, simultaneous growth curves of parental HDMECs at PDL 10 and hTERT(+) HDMECs at PDL 65 generated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (30) showed no significant differences during a 7-day period. Similar to previous studies in human skin fibroblast and RPE lines produced by hTERT expression (26, 27) hTERT(+) EC lines are contact-inhibited and exhibited normal pRb phosphorylation patterns in response to confluency-induced growth arrest (Fig. 5B). In addition, no changes in pRb phosphorylation patterns were observed upon growth arrest induced by either serum deprivation or hydroxyurea treatment when hTERT(+) ECs were compared with parental EC controls (Table II, data not shown). When anchorage-dependent growth was assessed using the soft agar assay, ECV304 cells formed colonies readily, whereas none of the hTERT-EC lines did (Fig. 5C). Taken together, these data suggest that, contrary to viral oncogene-induced or spontaneously transformed cell lines, hTERT(+) EC lines do not exhibit the growth or cell cycle control patterns of neoplastic, transformed cells even after growing in vitro for 2-5 times their respective life spans.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 5.   Growth and cell cycle control patterns of hTERT(+) ECs versus primary ECs. A, growth curves of four different hTERT(+) HUVEC clones and a single HAEC mass culture remained linear following continuous growth in vitro for 2-3 times the PDL of their respective parental EC controls. B, immunoblotting of pRb in primary HUVECs, HAECs, and HDMECs (upper panel) at subconfluency (S) or 72 h at confluency (C) showed comparable phosphorylation patterns to hTERT(+) ECs (lower panel). C, representative photomicrographs of colony formation in soft agar (see under "Materials and Methods"). None of our hTERT(+) EC strains (HAECs at PDL 127 used as an example) (right) formed colonies in soft agar, whereas the ECV304 transformed cell line did (left).

G banding and cytogenetic analyses showed that both parental HDMEC preparations we used had a normal male, diploid karyotype, and this was maintained upon hTERT immortalization (Fig. 6). Tetraploidy was observed in one hTERT(+) HDMEC line, hTERT1, at PDL 140; it was not seen at PDL 50. Another hTERT(+) HDMEC line, hTERT3, had no tetraploidy at PDL 75. No aneuploidy was observed in any parental or hTERT(+) HDMEC line. On the other hand, karyotypic abnormalities were found in both large vessel parental ECs, as well as hTERT(+) large vessel ECs, and these abnormalities were similar to the polyploid changes observed in late passage fibroblasts and hTERT(+) fibroblast lines (26). Parental large vessel ECs had at least 40% aneuploidy at early PDL, which increased to nearly 100% aneuploidy by late PDL. All large vessel hTERT(+) EC lines also had 100% aneuploidy, and thus hTERT expression did not prevent or reverse the genomic instability observed in parental ECs before hTERT expression (see Table II).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 6.   Karyotype of the hTERT(+) HDMEC line hTERT1 at PDL 50. Chromosomes were analyzed by GTW banding (see under "Materials and Methods"). The two parental HDMEC lines (at PDL 10 and 5, respectively) and both hTERT(+) HDMEC lines (hTERT1 and hTERT3 at PDL 50 and 75, respectively) all had normal diploid 46, XY male karyotype (20 metaphases for each). However, hTERT1 at PDL 140 were mostly tetraploid 92, XX YY (see Table II).

Taken altogether, these results indicate that introduction of telomerase into normal human ECs in vitro does not lead to abnormal growth patterns, cell transformation, or genomic instability.

Decreased Programmed Cell Death in hTERT(+) ECs-- Recent studies indicate that EC apoptosis is associated with important vascular remodeling patterns under both physiologic and pathologic conditions (45-50). Clarification of EC apoptotic mechanisms thus represents an important therapeutic strategy in the management of acute, chronic, and neoplastic diseases (51-53). Previous studies of human dermal fibroblasts showed that senescent cells are more resistant to apoptosis relative to young cells in vitro (54, 55). Therefore, we monitored the basal apoptotic rate in HDMECs and found that both early and late passage parental HDMECs showed lower nuclear fragmentation relative to mid passage HDMECs (Fig. 7A), with differences reaching statistical significance for PDL 15 versus both PDL 5 and 25. The effect of PDL on apoptosis in primary HDMEC cultures was verified by flow cytometric analysis of Apo2.7 positivity, reflecting the exposure of an early and specific mitochondrial apoptotic protein, 7A6 (38) (Fig. 7B). Two different hTERT-HDMEC lines showed statistically significant differences in baseline apoptotic rates versus each other, and both lines were comparable to early and late passage parental HDMECs (Fig. 7, A and B).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 7.   HDMEC programmed cell death as measured by nuclear fragmentation cell death ELISA (A and C) and flow cytometric analysis of mitochondrial Apo2.7 positivity (B and D) (see under "Materials and Methods"). A and B, basal levels of apoptosis in primary parental HDMECs showed a dynamic change as a function of PDL with higher rates at mid passage (PDL 15, double asterisks) versus early (PDL 5) or late (PDL 25). Basal apoptotic rates of two different hTERT-HDMEC lines (hTERT1 and hTERT3) remained stable with increasing PDL, but the HDMEC3 line was significantly less apoptotic versus both primary and hTERT-HDMEC1 (single asterisks). C, following induction of apoptosis by treatment with either TNF-alpha (0.1 µg/ml) + actinomycin D (1 µg/ml), lipopolysaccharide (0.1 µg/ml) + cycloheximide (50 µg/ml), UVC exposure (255 nm for 0.3 min), or serum starvation (40 h), both hTERT-HDMEC lines exhibited significantly lower nuclear fragmentation (asterisks) versus senescent primary HDMEC controls. D, the same trend was found for Apo2.7 flow cytometry; however, only lipopolysaccharide-induced apoptosis in hTERT-HDMEC1 reached statistical significance (asterisk). Statistical significance, <0.05. Experiments were repeated three times on hTERT-HDMECs. Results shown are represenative of three experiments.

Next, we compared apoptosis after stimulation with several different EC apoptotic inducers using the two hTERT-HDMEC lines and late passage, presenescent parental HDMECs as controls. Four different conditions for inducing EC apoptosis all showed the same result: hTERT(+) HDMECs resisted apoptotic induction relative to primary HDMECs (Fig. 7, C and D). Except for TNF-alpha  + actinomycin D induction in hTERT1 cells, both hTERT-HDMEC lines expressed statistically significant lower nuclear fragmentation versus controls in response to all treatments. Lipopolysaccharide + cycloheximide induction showed significantly decreased Apo2.7 expression in hTERT-HDMEC1 versus control, whereas other treatments did not reach statistical significance. The hTERT-HDMEC3 line that exhibited lower baseline apoptosis generally showed the lowest stimulated apoptotic rates. UV light-induced nuclear fragmentation and Apo2.7 expression appeared to reveal the most dramatic differences between primary and both hTERT HDMEC lines. Experiments assessing apoptosis resistance in large vessel hTERT(+) EC lines are under way, but preliminary studies using annexin V expression in HAECs after TNF-alpha  + actinomycin D induction showed a similar apoptosis resistance (data not shown).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In using five different types of human ECs, we have demonstrated the general applicability of using ectopic expression of hTERT to bypass replicative senescence while maintaining EC phenotypic and morphogenetic characteristics in vitro. Upon stable transfection or retroviral transduction of hTERT, telomerase activity was detectable in all ECs, and telomere lengths decreased with time in culture and then stabilized. To date, both hTERT-expressing clones and mass cultures have achieved a PDL (PDL 50-160) 2.5-5 times that of parental or control vector-transduced cells (PDL 30-50) and therefore are considered "immortal" (43). All hTERT-EC clones and different lines have been continuously passaged without evidence of altered morphology or changes in growth patterns.

Detailed analysis of EC phenotypic patterns revealed several important characteristics about hTERT-ECs. First, the various parental and hTERT-EC lines are typical of "partially activated" endothelium in vivo (14); however, the cell adhesion molecule expression profiles of senescent primary ECs (Fig. 4 and Table II) resembled that of inflammatory tissue (7-9). Second, hTERT-ECs underwent morphogenetic differentiation to form capillary-like structures in response to extracellular matrix signals, whereas senescent and transformed ECs did not (Fig. 3), and this may reflect an age-related functional defect in angiogenesis in vivo (1, 2). Third, similar to previous reports in other cell types, hTERT expression per se did not induce EC cytogenetic instability or a transformed phenotype (26, 27). Normal karyotypes were found in hTERT-HDMEC lines as in parental cells (Fig. 6 and Table II). hTERT-HUVEC clones and mass EC cultures were contact-inhibited, did not grow in soft agar, and exhibited appropriate pRb phosphorylation patterns in response to serum, cell density, and hydroxyurea-induced cell cycle arrest (Fig. 5, Table II). Finally, hTERT-HDMECs were more resistant to apoptotic induction than senescent parental controls or sham-transduced ECs (Fig. 7, C and D). Altogether, these results suggest that hTERT-ECs behave more like early passage, young ECs.

Telomere lengths in senescent ECs used in this study ranged between 5 and 7 kbp (data not shown), and our hTERT-HDMECs stabilized at 4-5 kbp (Fig. 1C). Previous studies in ECs (56), human fibroblasts (35), and various human cells (57) have shown that the mean TRF at senescence is approximately 4-7 kbp. hTERT immortalization of fibroblasts and RPE resulted in an increase and/or stabilization of telomere length to a size of >8 kbp (57). Thus, our hTERT-HUVEC clones with mean TRFs of 2-2.5 kbp (Fig. 1D) are well below those previously reported, and yet these cells bypassed senescence and continue to divide. Our results with hTERT(+) HUVEC clones are similar, however, to recent studies in hTERT(+) human fibroblast lines, which show a similar pattern of decreasing TRF with increasing PDL beyond the M2 crisis point (58). Possible reasons for these intrinsic differences in telomere lengths may relate to either cell type-specific mechanisms of telomere maintenance or threshold for functional telomerase of mass cell cultures versus individual clones.

Several studies have shown that genetic abnormalities occur in large vessel ECs (59, 60), but little is known about human microvascular EC cytogenetic instability. Our hTERT(+) HDMEC lines remained diploid after continuous passaging for 2-5 times their normal life spans. The tetraploid changes we observed in hTERT1 at PDL 140 are similar to many other human primary cells and immortalized cell lines that have been continuously grown in vitro for extended periods (76-78). However, the aneuploidy observed in both large vessel parental EC and hTERT-EC lines (Table II) indicates that hTERT expression does not appear to reverse these cytogenetic abnormalities. Because our hTERT-HDMEC lines showed a maintenance of normal karyotypes, these results suggest that hTERT expression per se does not induce chromosomal instability in human ECs. Recent studies in the mTR null mouse show critical interdependence of p53/p19, pRb/p16, p21, telomere dysfunction, and cell survival beyond the "genetic catastrophe" point (74, 75). Transformation into a neoplastic cell type in the mouse appears to depend on tolerance of genetic instability requiring certain adaptive responses, e.g. activation of oncogenes and/or telomerase, inactivation of tumor suppressors, etc. Our studies in hTERT(+) large vessel ECs show maintenance of normal growth rates and growth arrest patterns and absence of colony formation even in the face of cytogenetic instability at PDLs 2-4 times that of parental cells. These data suggest that a functional p53-dependent DNA damage checkpoint arrest pathway accompanying telomerase activation is important in preventing neoplastic transformation of large vessel human ECs.

The karyotypically normal hTERT(+) HDMECs exhibit a distinct survival advantage beyond that caused by hurdling the M1 senescence barrier (61), as these cells resist induction of apoptosis relative to senescent parental ECs under identical conditions. To our knowledge, this study is also the first to report EC apoptosis as a function of PDL, and our results indicate that senescent ECs were resistant to apoptosis relative only to midpassage primary ECs, not early passage cells, as reported previously in fibroblasts (54, 55). We used only confluent, growth-arrested cells for our apoptosis analyses as it is known that proliferating cells are more susceptable to apoptosis than are quiescent cells; however, unrepaired DNA and chromosomal damage are also known to trigger apoptotic induction (62-64, 74, 75). Only recently, it was found that DNA damage in the form of telomere shortening can be linked to either apoptosis or senescence, depending on a functional p53-dependent DNA checkpoint arrest pathway (65, 74, 75). A relationship between telomerase and apoptosis is apparent and it is known that telomerase functions to repair chromosomal damage induced by a wide variety of different agents that cause DNA strand breaks (66-69). Telomerase could thus be influencing nuclear fragmentation events observed in apoptosis, and several other studies support an inverse relationship between telomerase activity and programmed cell death (70-73).

Our results also support an inverse relationship between telomerase activity and apoptosis. The mechanism(s) of apoptotic resistance in telomerase-activated ECs is unclear, and further studies are in progress to clarify it. From the perspective of both potential therapeutic benefit and clarification of these possible mechanistic pathways, the development of an in vivo angiogenesis and vascular remodeling system incorporating hTERT(+) HDMECs becomes of paramount importance, and such studies are currently under way.

    ACKNOWLEDGEMENTS

We thank DanNing Zhang, David Lao, Ken Rolloma, Usha Nagavarapu, Bryan Gardner, Sharon Wong, XuRong Jiang, and Orlena Tam for expert technical assistance, Jackie Walker for administration assistance, and Dr. Woody Wright, University of Texas, Southwestern Medical Center (Dallas, Texas), for providing us with the retroviral vector pBabe-hTERT. Prof. Marvin A. Karasek is gratefully acknowledged for advice in the cultivation of HDMECs, and we thank Paul A. Khavari for help with the retroviral infection protocol.

    FOOTNOTES

* This work was supported by NIH PO-1 AR44012, the Carl J. Herzog Foundation, and the Dermatology Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ The first two authors contributed equally to this work.

** A Terman Fellow. To whom correspondence should be addressed: Dept. of Dermatology, MSLS Bldg. P205, Stanford University School of Medicine, Stanford, CA 94305-5486. Tel.: 650-725-2209; Fax: 650-723-8762; E-mail: gbh@leland.stanford.edu.

    ABBREVIATIONS

The abbreviations used are: EC, endothelial cell; HDMEC, human dermal microvascular EC; HUVEC, human umbilical vein EC; HSVEC, human saphenous vein EC; HAEC, human aortic EC; HCAEC, human coronary arterial EC; PECAM, platelet EC adhesion molecule; PDL, population doubling; hTERT, human telomerase reverse transcriptase; RPE, retinal pigment epithelial; TRAP, telomeric repeat amplification protocol; ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction; RT, reverse transcription; TRF, terminal restriction fragment; ICAM, intercellular adhesion molecule; TNF, tumor necrosis factor; 3D, three-dimensional; SA, senescence-associated; kbp, kilobase pair(s); pRb, retinoblastoma protein; LDL, low density lipoprotein; VCAM, vascular cell adhesion molecule.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Pili, R., Guo, Y., Chang, J., Nakanishi, H., Martin, G. R., and Passaniti, A. (1994) J. Natl. Cancer Inst. 86, 1303-1314[Abstract/Free Full Text]
2. Rivard, A., Fabre, J. E., Silver, M., Chen, D., Murohara, T., Kearney, M., Magner, M., Asahara, T., and Isner, J. M. (1999) Circulation 99, 111-120[Medline] [Order article via Infotrieve]
3. Cooper, L. T., Cooke, J. P., and Dzau, V. J. (1994) J. Gerontol. 49, B191-B196[Medline] [Order article via Infotrieve]
4. Kannel, W., and Gordon, T. (1980) in Cardiovascular Risk Factors in the Aged: The Farmingham Study (Haynes, S. , and Feinleib, S., eds) , pp. 65-98, National Institutes of Health, Bethesda, MD
5. West, M. D. (1994) Arch. Dermatol. 130, 87-95[Abstract]
6. Campisi, J. (1996) Cell 84, 497-500[CrossRef][Medline] [Order article via Infotrieve]
7. Maier, J. A., Statuto, M., and Ragnotti, G. (1993) Exp. Cell Res. 208, 270-274[CrossRef][Medline] [Order article via Infotrieve]
8. Comi, P., Chiaramonte, R., and Maier, J. A. (1995) Exp. Cell Res. 219, 304-308[CrossRef][Medline] [Order article via Infotrieve]
9. Maier, J. A., Voulalas, P., Roeder, D., and Maciag, T. (1990) Science 249, 1570-1574[Abstract/Free Full Text]
10. Tokunaga, O., Yamada, T., Fan, J. L., and Watanabe, T. (1991) Am. J. Pathol. 138, 941-949[Abstract]
11. Carrol, T., and Schroff, S. (1991) J. Clin. Invest. 87, 1002-1009
12. Sato, I., Morita, I., Kaji, K., Ikeda, M., Nagao, M., and Murota, S. (1993) Biochem. Biophys. Res. Commun. 195, 1070-1076[CrossRef][Medline] [Order article via Infotrieve]
13. Sholley, M. M., and Cotran, R. S. (1976) Am. J. Anat. 147, 243-254[CrossRef][Medline] [Order article via Infotrieve]
14. Cines, D. B., Pollak, E. S., Buck, C. A., Loscalzo, J., Zimmerman, G. A., McEver, R. P., Pober, J. S., Wick, T. M., Konkle, B. A., Schwartz, B. S., Barnathan, E. S., McCrae, K. R., Hug, B. A., Schmidt, A. M., and Stern, D. M. (1998) Blood 91, 3527-3561[Free Full Text]
15. Klagsbrun, M., and D'Amore, P. A. (1991) Annu. Rev. Physiol. 53, 217-239[CrossRef][Medline] [Order article via Infotrieve]
16. Folkman, J. (1995) Nat. Med. 1, 27-30[CrossRef][Medline] [Order article via Infotrieve]
17. Bicknell, R. (1996) in Endothelial Cell Culture (Bicknell, R., ed) , p. xii and 136, Cambridge University Press, Oxford, United Kingdom
18. Ades, E. W., Candal, F. J., Swerlick, R. A., George, V. G., Summers, S., Bosse, D. C., and Lawley, T. J. (1992) J. Invest. Dermatol. 99, 683-690[CrossRef][Medline] [Order article via Infotrieve]
19. Dubois, N. A., Kolpack, L. C., Wang, R., Azizkhan, R. G., and Bautch, V. L. (1991) Exp. Cell Res. 196, 302-313[CrossRef][Medline] [Order article via Infotrieve]
20. Candal, F. J., Rafii, S., Parker, J. T., Ades, E. W., Ferris, B., Nachman, R. L., and Kellar, K. L. (1996) Microvasc. Res. 52, 221-234[CrossRef][Medline] [Order article via Infotrieve]
21. Fontijn, R., Hop, C., Brinkman, H. J., Slater, R., Westerveld, A., van Mourik, J. A., and Pannekoek, H. (1995) Exp. Cell Res. 216, 199-207[CrossRef][Medline] [Order article via Infotrieve]
22. Cockerill, G. W., Meyer, G., Noack, L., Vadas, M. A., and Gamble, J. R. (1994) Lab. Invest. 71, 497-509[Medline] [Order article via Infotrieve]
23. Watanabe, Y., Lee, S. W., Detmar, M., Ajioka, I., and Dvorak, H. F. (1997) Oncogene 14, 2025-2032[CrossRef][Medline] [Order article via Infotrieve]
24. Watanabe, Y., and Dvorak, H. F. (1997) Exp. Cell Res. 233, 340-349[CrossRef][Medline] [Order article via Infotrieve]
25. Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., and Wright, W. E. (1998) Science 279, 349-352[Abstract/Free Full Text]
26. Jiang, X., Jimenez, G., Chang, E., Frolkis, M., Kusler, B., Sage, M., Beeche, M., Bodnar, A., Wahl, G., TlstyTlsty, T., and Chiu, C.-P. (1999) Nat. Genet. 21, 111-114[CrossRef][Medline] [Order article via Infotrieve]
27. Morales, C., Holt, S., Ouellette, M., Kaur, K., Yan, Y., Wilson, K., White, M., Wright, W., and Shay, J. (1999) Nat. Genet. 21, 115-118[CrossRef][Medline] [Order article via Infotrieve]
28. Kiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., and Klingelhutz, A. J. (1998) Nature 396, 84-88[CrossRef][Medline] [Order article via Infotrieve]
29. Karasek, M. A. (1989) J. Invest. Dermatol. 93 Suppl. 2, 33S-38S[CrossRef][Medline] [Order article via Infotrieve]
30. Romero, L. I., Zhang, D. N., Herron, G. S., and Karasek, M. A. (1997) J. Cell. Physiol. 173, 84-92[CrossRef][Medline] [Order article via Infotrieve]
31. Morgenstern, J. P., and Land, H. (1990) Nucleic Acids Res. 18, 3587-3596[Abstract/Free Full Text]
32. Kinsella, T. M., and Nolan, G. P. (1996) Hum. Gene Ther. 7, 1405-1413[Medline] [Order article via Infotrieve]
33. Kim, N. W., and Wu, F. (1997) Nucleic Acids Res. 25, 2595-2597[Abstract/Free Full Text]
34. Harley, C. B., Futcher, A. B., and Greider, C. W. (1990) Nature 345, 458-460[CrossRef][Medline] [Order article via Infotrieve]
35. Allsopp, R. C., Vaziri, H., Patterson, C., Goldstein, S., Younglai, E. V., Futcher, A. B., Greider, C. W., and Harley, C. B. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10114-10118[Abstract/Free Full Text]
36. Vaziri, H., Schächter, F., Uchida, I., Wei, L., Zhu, X., Effros, R., Cohen, D., and Harley, C. B. (1993) Am. J. Hum. Genet. 52, 661-667[Medline] [Order article via Infotrieve]
37. Levy, M. Z., Allsopp, R. C., Futcher, A. B., Greider, C. W., and Harley, C. B. (1992) J. Mol. Biol. 225, 951-960[CrossRef][Medline] [Order article via Infotrieve]
38. Koester, S. K., Roth, P., Mikulka, W. R., Schlossman, S. F., Zhang, C., and Bolton, W. E. (1997) Cytometry 29, 306-312[CrossRef][Medline] [Order article via Infotrieve]
39. Barch, M. J., and Knutsen, T. (eds) (1997) The AGT Cytogenetics Laboratory Manual , Vol. xiii , p. 666, Lippincott-Raven, New York
40. Seabright, M. (1971) Lancet 2, 971-972[Medline] [Order article via Infotrieve]
41. Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., Pereira-Smith, O., et al.. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9363-9367[Abstract/Free Full Text]
42. Hsiao, R., Sharma, H. W., Ramakrishnan, S., Keith, E., and Narayanan, R. (1997) Anticancer Res. 17, 827-832[Medline] [Order article via Infotrieve]
43. Shay, J. W., Pereira-Smith, O. M., and Wright, W. E. (1991) Exp. Cell Res. 196, 33-39[CrossRef][Medline] [Order article via Infotrieve]
44. Petzelbauer, P., Schechner, J., and Pober, J. (1999) in Endothelium: Dermatology in General Medicine (Freedberg, I. M. , Eisen, A. Z. , Wolff, K. , Austen, K. F. , Goldsmith, L. A. , Katz, S. I. , and Fitzpatrick, T. B., eds), Ed. 5, Vol. 1 , pp. 305-320, McGraw-Hill
45. Brooks, P., Montgomery, A., Rosenfeld, M., Reisfeld, R., Hu, T., Klier, G., and Cheresh, D. (1994) Cell 79, 1157-1164[CrossRef][Medline] [Order article via Infotrieve]
46. Lang, R., Lustig, M., Francois, F., Sellinger, M., and Plesken, H. (1994) Development 120, 3395-3403[Abstract]
47. Gobé, G., Browning, J., Howard, T., Hogg, N., Winterford, C., and Cross, R. (1997) J. Struct. Biol. 118, 63-72[CrossRef][Medline] [Order article via Infotrieve]
48. Sgonc, R., Grushwitz, M., Dietrich, H., Recheis, H., Gershwin, M., and Wick, G. (1996) J. Clin. Invest. 98, 785-792[Medline] [Order article via Infotrieve]
49. Kaplan, H. J., Leibole, M. A., Tezel, T., and Ferguson, T. A. (1999) Nat. Med. 5, 292-297[CrossRef][Medline] [Order article via Infotrieve]
50. Pollman, M. J., Naumovski, L., and Gibbons, G. H. (1999) J. Cell. Physiol. 178, 359-370[CrossRef][Medline] [Order article via Infotrieve]
51. Karsan, A. (1998) Tumor Necrosis Factor and Endothelial Cell Death , Vol. 8 , pp. 19-24, Elsevier Science Publishing Co., Inc., New York
52. Nor, J., Joan, C., Mooney, D., and Polverini, P. (1999) Am. J. Pathol. 154, 375-384[Abstract/Free Full Text]
53. Claesson-Welsh, L., Welsh, M., Ito, N., Anand-Apte, B., Soker, S., Zetter, B., O'Reilly, M., and Folkman, J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5579-5583[Abstract/Free Full Text]
54. Wang, E. (1995) Cancer Res. 55, 2284-2292[Abstract/Free Full Text]
55. Chang, E. H., Jang, Y. J., Hao, Z., Murphy, G., Rait, A., Fee, W. E., Jr., Sussman, H. H., Ryan, P., Chiang, Y., and Pirollo, K. F. (1997) Arch. Otolaryngol.-Head Neck Surg. 123, 507-512[Abstract]
56. Chang, E., and Harley, C. B. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11190-11194[Abstract/Free Full Text]
57. Counter, C. M., Hahn, W. C., Wei, W., Caddle, S. D., Beijersbergen, R. L., Lansdorp, P. M., Sedivy, J. M., and Weinberg, R. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14723-14728[Abstract/Free Full Text]
58. Zhu, J., Wang, H., Bishop, J., and Blackburn, E. (1999) Proc. Natl Acad. Sci. U. S. A. 96, 3723-3728[Abstract/Free Full Text]
59. Johnson, T. E., Umbenhauer, D. R., Hill, R., Bradt, C., Mueller, S. N., Levine, E. M., and Nichols, W. W. (1992) J. Cell. Physiol. 150, 17-27[CrossRef][Medline] [Order article via Infotrieve]
60. Nichols, W. W., Buynak, E. B., Bradt, C., Hill, R., Aronson, M., Jarrell, B. E., Mueller, S. N., and Levine, E. M. (1987) J. Cel. Physiol. 132, 453-462[CrossRef][Medline] [Order article via Infotrieve]
61. Harley, C., Vaziri, H., Counter, C., and Allsopp, R. (1992) Exp. Gerontol. 27, 375-382[CrossRef][Medline] [Order article via Infotrieve]
62. Meikarnatz, W., and Schlegel, R. (1995) J. Cell. Biochem. 58, 160-174[CrossRef][Medline] [Order article via Infotrieve]
63. King, K. L., and Cidlowski, J. A. (1995) J. Cell. Biochem. 58, 175-180[CrossRef][Medline] [Order article via Infotrieve]
64. Kasten, M., and Giordano, A. (1998) Cell Death Differ. 5, 132-140[CrossRef][Medline] [Order article via Infotrieve]
65. Karlseder, J., Broccoli, D., Dai, Y., Hardy, S., and de Lange, T. (1999) Science 283, 321-324[CrossRef]
66. Wilkie, A. O., Lamb, J., Harris, P. C., Finney, R. D., and Higgs, D. R. (1990) Nature 346, 868-871[CrossRef][Medline] [Order article via Infotrieve]
67. Morin, G. B. (1991) Nature 353, 454-456[CrossRef][Medline] [Order article via Infotrieve]
68. Flint, J., Craddock, C. F., Villegas, A., Ventley, D. P., Williams, H. J., Galandello, R., Cao, A., Wood, W. g., Ayyub, H., and Higgs, D. R. (1994) Am. J. Hum. Genet. 55, 505-512[Medline] [Order article via Infotrieve]
69. Hande, M. P., Lansdorp, P. M., and Natarajan, A. T. (1998) Mutat. Res. 404, 205-214[Medline] [Order article via Infotrieve]
70. Burger, A. M., Double, J. A., and Newell, D. R. (1997) Eur. J. Cancer 33, 638-644
71. Kondo, S., Tanaka, Y., Kondo, Y., Hitomi, M., Barnett, G. H., Ishizaka, Y., Liu, J., Haqqi, T., Nishiyama, A., Villeponteau, B., Cowell, J. K., and Barna, B. P. (1998) FASEB J. 12, 801-811[Abstract/Free Full Text]
72. Mandal, M., and Kumar, R. (1997) J. Biol. Chem. 272, 14183-14187[Abstract/Free Full Text]
73. Fu, W., Begley, J., Killen, M., and Mattson, M. (1999) J. Biol. Chem. 274, 7264-7271[Abstract/Free Full Text]
74. Greenberg, R., Chin, L., Femino, A., Lee, K., Gottlieb, G., Singer, R., Greider, C., and DePinho, R. (1999) Cell 97, 515-525[CrossRef][Medline] [Order article via Infotrieve]
75. Chin, L., Artandi, S., Shen, Q., Tam, A., Lee, S., Gottlieb, G., Greider, C., and DePinho, R. (1999) Cell 97, 527-538[CrossRef][Medline] [Order article via Infotrieve]
76. Gordon, D., Mohai, L., and Schwartz, S. (1986) Circ. Res. 59, 633-644[Abstract]
77. Kaji, K., and Matsuo, M. (1981) Exp. Cell Res. 131, 410-412[CrossRef][Medline] [Order article via Infotrieve]
78. Matsumura, T. (1980) Adv. Exp. Med. Biol. 129, 31-38[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.



This article has been cited by other articles:


Home page
BloodHome page
P. Au, L. M. Daheron, D. G. Duda, K. S. Cohen, J. A. Tyrrell, R. M. Lanning, D. Fukumura, D. T. Scadden, and R. K. Jain
Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels
Blood, February 1, 2008; 111(3): 1302 - 1305.
[Abstract] [Full Text] [PDF]


Home page
Card Surg AdultHome page
R. P. Gallegos and R. M. Bolman III
Stem Cell Induced Regeneration of Myocardium
Card. Surg. Adult, January 1, 2008; 3(2008): 1657 - 1668.
[Full Text]